Scisparc Ltd
NASDAQ:SPRC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Scisparc Ltd
Operating Expenses
Scisparc Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Scisparc Ltd
NASDAQ:SPRC
|
Operating Expenses
-$6.5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-13%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Operating Expenses
-$50.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-6%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Operating Expenses
-$14.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-1%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Operating Expenses
-$222.2m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Operating Expenses
-$10.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Operating Expenses
-$25.4m
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
0%
|
|
Scisparc Ltd
Glance View
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
See Also
What is Scisparc Ltd's Operating Expenses?
Operating Expenses
-6.5m
USD
Based on the financial report for Dec 31, 2024, Scisparc Ltd's Operating Expenses amounts to -6.5m USD.
What is Scisparc Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-13%
Over the last year, the Operating Expenses growth was 19%. The average annual Operating Expenses growth rates for Scisparc Ltd have been -4% over the past three years , -10% over the past five years , and -13% over the past ten years .
